Our site uses cookies to offer a better navigation functionality, including "third party" cookies and "profiling cookies" designed to send on-line commercial communications in line with the preferences expressed by the user while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here to disable them. Upon proceeding with browsing this website, you will be consenting to the use of cookies.
MEN1309

Monoclonal human antibody conjugated to a toxin against B-Non Hodgkin lymphoma and solid tumors such a subtype of breast cancer.

Current development phase : pre-clinical


MEN1309 is the second monoclonal antobody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics).

MEN 1309 is a human monoclonal antibody conjugated to a potent cytotoxic agent, maytansin derivative, against a membrane antigen which is over-expressed in many tumors such non-Hodgkin lymphoma (NHL) and solid tumors such a subtype of breast cancer 


Aree terapeutiche

 

Discover all of Menarini's products marketed in Italy.

READ MORE »

Diagnostica

 

Advanced Technology

READ MORE »

Il gruppo Menarini

 

Discover the leading Italian pharmaceutical company in the world.

READ MORE »

La qualità al primo posto

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »